Real-World Effectiveness of Nirmatrelvir–Ritonavir in Preventing Severe COVID-19 in Taiwan

Overview

This large nationwide cohort study in Taiwan demonstrated that outpatient treatment with nirmatrelvir–ritonavir significantly reduced the risk of severe COVID-19 outcomes, including hospitalization, ICU admission, invasive ventilation, and death. The antiviral was effective across all age groups and vaccination statuses, with the greatest benefits observed in unvaccinated patients and older adults with additional risk factors.

Background

COVID-19 has caused substantial global morbidity and mortality, with Taiwan experiencing over 10 million cases and 15,000 deaths by late 2024. Antiviral therapies such as nirmatrelvir–ritonavir have been critical in mitigating severe disease, especially during the Omicron surge. While clinical trials and meta-analyses have shown efficacy in reducing hospitalization and death, real-world data in East Asian populations and across different vaccination statuses remain limited. This study addresses these gaps by analyzing comprehensive nationwide data from Taiwan's National Health Insurance Research Database.

Data Highlights

Key Findings

• Nirmatrelvir–ritonavir treatment was associated with a 68% reduction in COVID-19-related hospitalization risk.
• Risk of ICU admission decreased by 59% among treated patients compared to untreated.
• Use of invasive ventilatory support was reduced by 62% with antiviral treatment.
• Mortality risk was lowered by 58% in patients receiving nirmatrelvir–ritonavir.
• Effectiveness was consistent regardless of age or vaccination status, with greatest benefit in unvaccinated individuals and those aged ≥65 years with additional risk factors.

Clinical Implications

Early outpatient administration of nirmatrelvir–ritonavir should be considered to reduce severe COVID-19 outcomes, especially in older adults and unvaccinated patients with risk factors. These findings support prioritizing antiviral treatment in high-risk populations to alleviate healthcare burden and improve patient prognosis during COVID-19 surges.

Conclusion

This comprehensive nationwide study confirms that nirmatrelvir–ritonavir significantly reduces severe COVID-19 outcomes in a real-world East Asian population, reinforcing its role as an essential early treatment option across diverse patient subgroups.

References

1. Taiwan National Health Insurance Research Database 2022 -- Nationwide Cohort Study on COVID-19
2. EPIC-HR Trial 2022 -- Nirmatrelvir–Ritonavir for COVID-19 Treatment
3. WHO COVID-19 Global Data 2024 -- Pandemic Impact and Mortality
4. Meta-analyses 2023-2024 -- Real-World Effectiveness of Nirmatrelvir–Ritonavir